Advertisement

Topics

Ataxia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

20:32 EDT 21 Aug 2017 | BioPortfolio Reports

DelveInsight's, Ataxia Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Ataxia. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Ataxia. This report provides information on the therapeutic development for Ataxia, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
AbbVie
Adverum Biotechnologies Inc.
Agilis Biotherapeutics
Bach Pharma
Baxter Healthcare Corporation
BioBlast Pharma
Biohaven Pharma
Biovista
Cardero Therapeutics Inc.
Catabasis Pharmaceuticals
Edison Pharmaceuticals
Ixchel Pharma
Jupiter Orphan Therapeutics
Kissei Pharmaceutical Co. Ltd.
Neuraltus Pharmaceuticals
NsGene
Pfizer
ProQR Therapeutics
Rana Therpeutics
Reata Pharmaceuticals
Recursion Pharma
Retrotope
Shire
Steminent Biotherapeutics
Strategics Inc.
Takeda
Voyager therapeutics
Vybion
Ataxia Pipeline Drugs
Ataxia Pipeline Assessment
Ataxia Pipeline Analysis
Ataxia Drugs under Development
Ataxia Discovery drugs
Ataxia Preclinical drugs
Ataxia Phase I drugs
Ataxia Phase II drugs
Ataxia Phase III Pipeline Drugs Assessment
Ataxia Preregistration drugs
Ataxia Molecules in pipeline

Original Article: Ataxia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Ataxia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...